acromegaly

Octreotide (SMS 201-995) is a potent inhibitor of growth hormone, glucagon, and insulin.

L-692429 (MK-0751) is a potent nonpeptidyl growth hormone secretagogue (GHS) agonist and benzolactam derivative, known for reversing glucocorticoid-induced inhibition of GH secretion. L-692429 exhibits high affinity for the G protein-coupled receptor and is useful in studying acromegaly and obesity.

Lanreotide, a somatostatin analogue, suppresses GH/IGF-I hypersecretion in acromegaly patients. It also used to manage neuroendocrine tumours.

Tezusomant is an antagonist of the growth hormone receptor (growth hormone receptor). It is being investigated for potential use in conditions like acromegaly, which are caused by excessive secretion of growth hormone.

BIM-23190 hydrochloride, a selective agonist for somatostatin receptors SSTR2 and SSTR5 with Ki values of 0.34 nM and 11.1 nM respectively, is a somatostatin analog utilized in research on cancer and acromegaly[1][3].

BIM-23190 is a somatostatin analog that acts as a selective agonist for SSTR2 and SSTR5 receptors. It displays potency with K i values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 finds utility in cancer and acromegaly research.

BIM-23190 aceate, a somatostatin analog, a selective agonist of SSTR2 and SSTR5. BIM-23190 can be used in cancer and acromegaly studies.

Paltusotine is a nonpeptide, small molecule somatostatin type 2 (SST2) receptor agonist with high oral bioavailability. Paltusotine maintains GH and IGF-1 levels in acromegaly patients

DSPE-PEG1000-Octreotide, a PEG compound formed from DSPE and Octreotide, acts as a somatostatin receptor agonist. Octreotide exhibits antitumor properties and induces apoptosis, making it useful in researching acromegaly. Additionally, DSPE-PEG1000-Octreotide is applicable in drug delivery.

DSPE-PEG2000-Octreotide is a PEG compound composed of DSPE and Octreotide. Octreotide serves as a somatostatin receptor agonist with antitumor properties, mediating apoptosis and applicable in acromegaly research. DSPE-PEG2000-Octreotide is employed in drug delivery systems.

DSPE-PEG5000-Octreotide is a PEG compound composed of DSPE and Octreotide. Octreotide serves as a somatostatin receptor agonist and exhibits anti-tumor properties, induces apoptosis, and is applicable for acromegaly research. DSPE-PEG5000-Octreotide can be utilized in drug delivery.

DSPE-PEG3400-Octreotide is a PEG compound composed of DSPE and Octreotide. Octreotide acts as a somatostatin receptor agonist with antitumor properties and mediates apoptosis, and it is also applicable in the study of acromegaly. DSPE-PEG3400-Octreotide can be utilized for drug delivery purposes.

Pasireotide (SOM230) acetate is a long-acting cyclohexapeptide growth hormone inhibitory hormone analog with antisecretory, antiproliferative, and proapoptotic activities.Pasireotide (SOM230) acetate inhibits the secretion of GH, IGF-I, and ACTH, and can be used in the study of acromegaly and Cushing's disease. Pasireotide (SOM230) acetate also enhances the agonist activity of growth inhibitory receptors, with pKi of 8.2, 9.0, 9.1, <7.0 and 9.9 for sst1, 2, 3, 4 and 5, respectively.